[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP1135135A4 - Chk1 kinase inhibitors - Google Patents

Chk1 kinase inhibitors

Info

Publication number
EP1135135A4
EP1135135A4 EP99969337A EP99969337A EP1135135A4 EP 1135135 A4 EP1135135 A4 EP 1135135A4 EP 99969337 A EP99969337 A EP 99969337A EP 99969337 A EP99969337 A EP 99969337A EP 1135135 A4 EP1135135 A4 EP 1135135A4
Authority
EP
European Patent Office
Prior art keywords
kinase inhibitors
chk1 kinase
chk1
inhibitors
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99969337A
Other languages
German (de)
French (fr)
Other versions
EP1135135A1 (en
Inventor
Aidan G Gilmartin
Maureen L Ho
Christina S Imburgia
Amy K Roshak
Maria Amparo Lago
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1135135A1 publication Critical patent/EP1135135A1/en
Publication of EP1135135A4 publication Critical patent/EP1135135A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP99969337A 1998-09-18 1999-09-17 Chk1 kinase inhibitors Withdrawn EP1135135A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10101698P 1998-09-18 1998-09-18
US101016P 1998-09-18
PCT/US1999/021433 WO2000016781A1 (en) 1998-09-18 1999-09-17 Chk1 kinase inhibitors

Publications (2)

Publication Number Publication Date
EP1135135A1 EP1135135A1 (en) 2001-09-26
EP1135135A4 true EP1135135A4 (en) 2006-08-09

Family

ID=22282686

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99969337A Withdrawn EP1135135A4 (en) 1998-09-18 1999-09-17 Chk1 kinase inhibitors

Country Status (3)

Country Link
EP (1) EP1135135A4 (en)
JP (1) JP2002526450A (en)
WO (1) WO2000016781A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094798B1 (en) 2002-04-26 2006-08-22 Pfizer Inc Inhibitors of checkpoint kinases (Wee1 and Chk1)
WO2004063198A1 (en) 2003-01-09 2004-07-29 Pfizer Inc. Diazepinoindole derivatives as kinase inhibitors
DE602004017479D1 (en) 2003-08-29 2008-12-11 Pfizer THIENOPYRIDINPHENYLACETAMIDES SUITED AS NEW ANTIANGIOGENIC AGENTS AND DERIVATIVES THEREOF
EP2330105A1 (en) 2005-03-29 2011-06-08 ICOS Corporation Heteroaryl urea derivatives useful for inhibiting CHK1
EP2409700A1 (en) 2007-05-08 2012-01-25 Schering Corporation Methods of treatment using intravenous formulations comprising temozolomide
WO2010016005A1 (en) 2008-08-06 2010-02-11 Pfizer Inc. 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors
GB0911042D0 (en) * 2009-06-25 2009-08-12 Istituto Superiore Di Sanito Treatment of tumorigenic cells in solid tumours
EP2872631B1 (en) * 2012-07-13 2017-05-03 Turun yliopisto Combination therapy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63295589A (en) * 1987-01-22 1988-12-01 Kyowa Hakko Kogyo Co Ltd Derivative of physiologically active substance k-252
US5043335A (en) * 1989-07-25 1991-08-27 Godecke Aktiengesellschaft Indolocarbazoles and the use thereof
JPH05271238A (en) * 1992-03-25 1993-10-19 Meiji Seika Kaisha Ltd New sf2370 derivative
JPH08319238A (en) * 1995-05-24 1996-12-03 Asahi Chem Ind Co Ltd Phosphorylase inhibitor
WO1997005140A1 (en) * 1995-07-31 1997-02-13 Novartis Ag Trindene compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5621101A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63295589A (en) * 1987-01-22 1988-12-01 Kyowa Hakko Kogyo Co Ltd Derivative of physiologically active substance k-252
US5043335A (en) * 1989-07-25 1991-08-27 Godecke Aktiengesellschaft Indolocarbazoles and the use thereof
JPH05271238A (en) * 1992-03-25 1993-10-19 Meiji Seika Kaisha Ltd New sf2370 derivative
JPH08319238A (en) * 1995-05-24 1996-12-03 Asahi Chem Ind Co Ltd Phosphorylase inhibitor
WO1997005140A1 (en) * 1995-07-31 1997-02-13 Novartis Ag Trindene compounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 198903, Derwent World Patents Index; Class B02, AN 1989-019684, XP002384518 *
DATABASE WPI Section Ch Week 199346, Derwent World Patents Index; Class B02, AN 1993-365224, XP002384519 *
PATENT ABSTRACTS OF JAPAN vol. 1997, no. 04 30 April 1997 (1997-04-30) *
See also references of WO0016781A1 *

Also Published As

Publication number Publication date
EP1135135A1 (en) 2001-09-26
JP2002526450A (en) 2002-08-20
WO2000016781A1 (en) 2000-03-30

Similar Documents

Publication Publication Date Title
EG24381A (en) Tyrosine kinase inhibitors
HUP0202713A3 (en) Pteridinones as kinase inhibitors
EP1161433A4 (en) Tyrosine kinase inhibitors
AU3704101A (en) Kinase inhibitors
IL141724A0 (en) INHIBITORS OF P38-α KINASE
GB9900416D0 (en) Inhibitors
PL337697A1 (en) Farnesil-proteinous transferase inhibitors
SK6862001A3 (en) Substituted pyrazoles as p38 kinase inhibitors
HK1049154A1 (en) 2-pyrazolin-5-ones as tyrosine kinase inhibitors
IL148719A0 (en) Kinase inhibitors as therapeutic agents
AU2001237041A1 (en) Kinase inhibitors
GB2352395B (en) Paroxetine methanesulfonate
HK1042695A1 (en) Prothease inhibitors
EP1135135A4 (en) Chk1 kinase inhibitors
EP1056450A4 (en) Farnesyl-protein transferase inhibitors
EP1135126A4 (en) Myt1 kinase inhibitors
GB2389113B (en) B-secretase inhibitor
GB9806743D0 (en) Cyclin dependent kinase inhibitors
GB9803416D0 (en) Inhibitors
GB9828697D0 (en) Inhibitors
GB9826992D0 (en) Inhibitors
PT986382E (en) Raf kinase inhibitors
GB9929341D0 (en) Inhibitors
GB9929340D0 (en) Inhibitors
GB9917294D0 (en) Inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010309

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20060710

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 27/02 20060101ALI20060630BHEP

Ipc: A61P 19/02 20060101ALI20060630BHEP

Ipc: A61P 35/00 20060101ALI20060630BHEP

Ipc: A61K 31/55 20060101AFI20000403BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061006